
    
      This is a Phase 2, multicenter, double-blind, placebo-controlled, parallel-group study
      consisting of a screening period of up to 4 weeks, a 4 week randomized double-blind,
      dose-titration treatment period, followed by a 1 week safety follow-up period after the last
      dose of study medication, and a scheduled follow-up safety telephone call one week later.

      Subjects will be randomized 1:1 to one of two treatment groups. Group A will receive
      titrating doses of CX-8998 up to 10 mg BID and Group B will receive placebo.

      Subjects will participate for a total of up to 12 weeks, including screening, the 4-week
      treatment period and follow-up.
    
  